

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 20, 2004 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/669,175
Sheet 1 of 3				Filing Date	09/23/2003
				First Named Inventor	Nicole Zitzmann
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	080618-0304

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/MH/	A1	6,355,413	B1	Gage et al.	03/12/2002	
	A2	6,291,657	B1	Platt et al.	09/18/2001	
	A3	5,622,972		Bryant et al.	04/22/1997	
	A4	5,580,884		Platt et al.	12/03/1996	
	A5	5,310,745		Partis et al.	05/10/1994	
	A6	5,286,877		Behling et al.	02/15/1994	
	A7	5,200,523		Fleet	04/06/1993	
	A8	5,100,797		Fleet et al.	03/31/1992	
	A9	5,043,273		Scudder et al.	08/27/1991	
	A10	5,017,704		Fleet et al.	05/21/1991	
	A11	5,013,842		Fleet et al.	05/07/1991	
	A12	5,011,929		Fleet et al.	04/30/1991	
	A13	4,996,329		Fleet et al.	02/26/1991	
	A14	4,944,572		Young	07/31/1990	
	A15	4,910,310		Campbell et al.	03/20/1990	
	A16	4,894,388		Fleet	01/16/1990	
	A17	4,861,892		Fleet	08/29/1989	
	A18	4,806,650		Schröder et al.	02/21/1989	
	A19	4,405,714		Kinast et al.	09/20/1983	
	A20	4,266,025		Kinast et al.	05/05/1981	
	A21	4,246,345		Kinast et al.	01/20/1981	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A22		WO 01/10429	A2	Zitzmann et al.	02/15/2001		
	A23		WO 99/24401	A1	G.D. Searle & Company	05/20/1999		
	A24		WO 98/35685	A1	Jacob et al.	08/20/1998		
	A25		EP0 465 098	A2	G.D. Searle & Company	02/25/1991		
			445					

Examiner Signature	/Michelle Horning/	Date Considered	05/25/2007
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO). ⁴ Enter the serial number of the patent document. ⁵ Enter the kind code of the patent document. ⁶ Enter the indication of the year of the reign of the Emperor must precede the serial number of the patent document.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 20, 2004

(use as many sheets as necessary)

Complete if Known

Application Number	10/669,175
Filing Date	09/23/2003
First Named Inventor	Nicole Zitzmann
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	080618-0304

Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/MH/	A26	BERGERON et al., "Calnexin: a membrane-bound chaperone of the endoplasmic reticulum," TIBS 19 - March 1994, Elsevier Scient Ltd. 0968-0004/94 pp. 124-128.	
	A27	BRANZA-NICHITA et al., "Antiviral of N-Butyldesoxynojirimycin against Bovine Viral Diarrhea Virus Coorelates with Misfolding of E2 Envelope Proteins and Impairment of Their Association into E1-E2 Heterodimers," (2001) J. Virol. 75(8), pp. 3527-36.	
	A28	CARRERE-KREMER et al., "Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus, (2002) J. Virol. 76(8), pp. 3720-30.	
	A29	CHOUKHI et al., "Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins, (1998) J. Virol., 72(5), pp. 3851-8.	
	A30	COURAGEOT et al., "α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum," (2000) J. Virol., 74(1): pp. 564-72.	
	A31	DUFF et al., "The Transmembrane Domain of Influenza A M2 Protein Forms Amantadine-Sensitive Proton Channels in Planar Lipid Bilayers," Virology 190, pp. 485-489 (1992) 0042-6822/92 Copyright 1992 by Academic Press, Inc.	
	A32	DURANTEL et al., "Study of the Mechanism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus," (2001) J. Virol. 75(19): pp. 8987-98.	
	A33	DWEK, et al., "Targeting Glycosylation as a Therapeutic Approach," Nature Reviews/Drug Discovery, Vol. 1, January 2002, pp. 65-75. Glycobiology Institute, Dept. of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.	
	A34	FISCHER et al., "Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B," Eur. Biophys J. (2001) 3-: pp. 416-420, DOI 10.1007/s00240100157.	
	A35	GRIFFIN et al., "The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine," FEBS Letters 535 (2003) pp. 34-38, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.	
	A36	HARADA et al., "E2-p7 Region of the Bovine Viral Diarrhea Virus Polyprotein: Processing and Functional Studies," (2000) J. Virol. 74(20): pp. 9498-506.	
	A37	HAY et al., "The molecular basis of the specific anti-influenza action of amantadine," EMBO Journal, Vol. 4 no. 11 pp. 3021-3024, 1985. Oxford, England.	
	A38	LIN et al., "Processing in the Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products with Different C Termini," (1994) J. Virol. 68(8): pp. 5063-73.	
	A39	LOHMANN et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," (1999) Science, 285(5424) pp. 110-3.	
	A40	MEHTA et al., "α-Glucosidase inhibitors as potential broad based anti-viral agents," FEBS Lett. 1998 June 23; 430(1-2): pp. 17-22.	

Examiner
Signature


/Michelle Horning/

Date
Considered

05/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 31) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document



MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 20, 2004 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/669,175
				Filing Date	09/23/2003
				First Named Inventor	Nicole Zitzmann
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	080618-0304
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
/MH/ ↓ ↓	A41	MIZUSHIMA et al., "Two Hepatitis C Virus Glycoprotein E2 Products with Different C Termini," (1994) J. Virol. 68(10); pp. 6215-22.		
	A42	MONTAL et al., "Formation of Bimolecular Membranes from Lipid Monolayers and a Study of Their Electrical Properties," Proc. Nat. Acad. Sci. USA 69 (1972) pp. 3561-3566.		
	A43	PAVLOVIC et al., "The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives," PNAS 2003, May 13; 100(10): pp. 6104-8.		
	A44	PETERSON et al., "Transient, Lectin-like Association of Calreticulin with Folding Intermediates of Cellular and Viral Glycoproteins," Molecular Biology of the Cell, Vol. 6, pp. 1173-1184, September 1995 by The American Society for Cell Biology.		
	A45	PIETSCHMANN et al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs," (2001) J. Virol. 75(3); pp. 1252-64.		
	A46	REED et al., "Overview of Hepatitis C Virus Genome Structure, Polyprotein Processing, and Protein Properties," Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, pp. 55-84.		
	A47	SUNSTROM, et al., "Ion Channels Formed by NB, an Influenza B Virus Protein," J. Membrane Biol. 150, pp. 127-132 (1996)		
	A48	WU et al., "Antiviral Effects of an Iminosugar Derivative on Flavivirus Infections," (2002) J. Virol., 76(8): pp. 3596-604.		
	A49	XU et al., "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," (2001) The EMBO Journal 20(14): pp. 3840-8.		
	A50	ZITZMANN, et al., "Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents," (2001) Proc. Natl. Acad. Sci. USA, Oct. 12, (21): pp. 11878-82.		

Examiner Signature	/Michelle Horning/	Date Considered	05/24/2007
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.